Cancer
Moderna readies production of Merck-partnered cancer vaccine
Moderna says it is ready to produce thousands of doses of its Merck-partnered cancer vaccine ahead of an FDA marketing application planned by year-end.

Moderna is preparing commercial production of its personalized cancer vaccine developed with Merck, as it plans to file a marketing application with the FDA by the end of this year, Endpoints News reported. The company said it is “on track and ready” to make thousands of doses.
TIME reported that the vaccine, intismeran, is used with one of Merck’s drugs. The companies announced in October that the approach stimulated the immune system to fight cancer, and the combination kept melanoma from recurring in a group of patients with mid- to late-stage disease. The reports did not say when the FDA is expected to decide on the application.


